GlassScriptPhysician profile
Celeste S Trice
NPI 1265993364
$1,375.31
in general payments reported to CMS, 2019-2025
25 companies · $802 in 2025
The $802 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.69 · 2022: $44.84 · 2023: $60.76 · 2024: $410 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.85 |
| Education | $273.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $189.94 | 2024-2025 | |
| Pfizer INC. | $157.15 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $147.37 | 2024-2025 | |
| Lilly USA, LLC | $124.60 | 2024-2025 | Verzenio, Retevmo, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $95.87 | 2021-2025 | Opdivo |
| Alexion Pharmaceuticals, INC. | $83.99 | 2024 | Soliris |
| Incyte Corporation | $79.41 | 2025 | Jakafi, Monjuvi, Zynyz |
| Astrazeneca Pharmaceuticals LP | $64.70 | 2025 | Imfinzi, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $58.53 | 2024-2025 | Iclusig |
| Array Biopharma INC | $46.07 | 2025 | Braftovi, Mektovi, Tukysa |
| Beigene USA, INC. | $40.41 | 2024-2025 | Brukinsa |
| Astellas Pharma US INC | $29.65 | 2025 | Vyloy |
| Emd Serono, INC. | $27.94 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.65 | 2025 | |
| Tersera Therapeutics LLC | $24.29 | 2025 | Quzyttir |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $21.75 | 2023 | Rezlidhia, Tavalisse |
| Cti Biopharma Corp. | $21.32 | 2023 | Vonjo |
| Glaxosmithkline, LLC. | $20.31 | 2025 | Ojjaara |
| Janssen Biotech, INC. | $18.44 | 2025 | Akeega, Balversa, Erleada |
| Genmab U.S., INC. | $17.87 | 2025 | Epkinly |
| Taiho Oncology, INC. | $17.69 | 2023 | |
| Genzyme Corporation | $17.48 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.81 | 2022 | |
| Beone Medicines USA, INC. | $15.16 | 2025 | Brukinsa |
| Eisai INC. | $13.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Trice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.